Hematology/Oncology

Top Story

Histologic regression may predict SLNB benefit in melanoma

September 2, 2015

Sentinel lymph node positivity occurred less frequently in patients with primary melanoma who had histologic regression, according to the results of a systemic review and meta-analysis.

Histologic regression may, thus, serve as a prognostic indicator for selecting which patients should undergo sentinel lymph node biopsy, according to the researchers.

Meenakshi Bewtra In the Journals

Radiofrequency ablation reduces neoplastic progression in Barrett's esophagus

September 2, 2015
Patients with Barrett’s esophagus and confirmed low-grade dysplasia who underwent radiofrequency ablation had lower rates of neoplastic progression, according to…
Hayden McRobbie In the Journals

Carbon monoxide, acrolein decrease in smokers who switch to e-cigarettes

September 2, 2015
E-cigarette use in smokers who quit and in dual users demonstrated a significant decrease in tobacco smoke toxicant exposure, according to study results.“We found…
In the Journals

Survival favorable among younger patients with rectal cancer despite unfavorable tumor morphology

September 2, 2015
Younger patients with rectal cancer have comparable survival outcomes as middle-aged patients despite more frequently presenting with advanced disease and unfavorable…
In the Journals

Erivedge shows promise as treatment for radiation-induced multiple BCCs

September 2, 2015
Erivedge provided a significant clinical response and was a relatively safe alternative therapy for patients with radiation-induced multiple basal cell carcinomas…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
morganatic-roan